Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein ( rFIXFc ) in subjects with haemophilia

K. John Pasi1; Kathelijn Fischer2; Margaret Ragni3; Beatrice Nolan4; David J. Perry5; Roshni Kulkarni6; Margareth Ozelo7; Johnny Mahlangu8; Amy D. Shapiro9; Ross I. Baker10; Carolyn M. Bennett11; Christopher Barnes12; Johannes Oldenburg13; Tadashi Matsushita14; Huixing Yuan15; Alejandra Ramirez-Santiago15; Glenn F. Pierce15; Geoffrey Allen15; Baisong Mei15 1Royal London Haemophilia Centre, Barts and The London School of Medicine and Dentistry, London, UK; 2Van Creveldkliniek, University Medical Center, Utrecht, The Netherlands; 3Hemophilia Center of Western Pennsylvania, University of Pittsburgh, Pittsburgh, Pennsylvania, USA; 4Our Lady’s Children’s Hospital, Dublin, Ireland; 5Addenbrookes Hospital, Cambridge, UK; 6Michigan State University, East Lansing, Michigan, USA; 7INCT do Sangue Hemocentro UNICAMP, University of Campinas, Brazil; 8Haemophilia Comprehensive Care Centre, Faculty of Health Sciences, University of the Witwatersrand, Charlotte Maxeke Johannesburg Academic Hospital and NHLS, Johannesburg, South Africa; 9Indiana Hemophilia and Thrombosis Center, Indianapolis, Indiana, USA; 10Western Australian Centre for Thrombosis and Haemostasis, Murdoch University, Perth, Western Australia, Australia; 11Emory University School of Medicine, Children’s Healthcare of Atlanta, Aflac Cancer and Blood Disorders Center, Atlanta, Georgia, USA; 12The Royal Children’s Hospital, Parkville, Melbourne, Victoria, Australia; 13Institute of Experimental Haematology and Transfusion Medicine, University of Bonn, Bonn, Germany; 14Department of Transfusion Medicine, Nagoya University Hospital, Nagoya, Japan; 15Biogen, Cambridge, Massachusetts, USA